Profiel
Liisa I.
Nogelo worked as an Associate General Counsel at Biogen, Inc. from 2007 to 2018.
She also worked as the General Counsel at The Broad Institute, Inc. from 2014 to 2018.
Her most recent job was as Secretary & Chief Legal Officer at Surface Oncology, Inc. from 2020 to 2022.
Nogelo received her undergraduate degree from Wellesley College and her graduate degree from UCLA School of Law.
Eerdere bekende functies van Liisa I. Nogelo
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01-07-2018 |
The Broad Institute, Inc.
 The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Algemeen Adviseur | 01-07-2018 |
| SURFACE ONCOLOGY, INC. | Algemeen Adviseur | 01-02-2022 |
Opleiding van Liisa I. Nogelo
| Wellesley College | Undergraduate Degree |
| UCLA School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOGEN INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
